Loading...
Loading...
Response Genetics, Inc.
, a company focused on the development and sale of molecular
diagnostic tests for cancer, today announced the acquisition of all of the key
assets of Pathwork Diagnostics, including its FDA-cleared, Medicare-reimbursed
test for the diagnosis of metastatic, poorly differentiated and
undifferentiated cancer.
Terms of the deal include a $200,000 cash payment and issuance of 500,000
shares of Response Genetics common stock with a lock-up period through June
2014. The Company expects the deal to be accretive within its first full year
of acquisition.
The acquired assets and associated test use a proprietary microarray platform
and proprietary software to compare the expression of 2,000 genes in a
patient's tumor with a panel of 15 known tumor types that represent 90% of all
cancers. The test received FDA clearance in June 2010 and is the most
published, extensively validated molecular diagnostic test of its kind. Prior
to its acquisition by Response Genetics, the test generated rapidly growing
sales including 2012 sales dollar volume in the mid-seven figure range.
The identity of most tumors can be determined using traditional methods.
However, when tumors are poorly differentiated or metastatic with no clear
primary origin, providing a definitive diagnosis is usually very difficult or
nearly impossible to determine. It is estimated that up to 150,000
newly-diagnosed cancer patients annually, in just the U.S., may have a tumor
for which the site of origin is uncertain after the initial diagnostic workup.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in